Enhancing Mural Nodules in the Main Pancreatic Duct of Main and Mixed Types of Intraductal Papillary Mucinous Neoplasms: Does Size Matter in Malignancy Risk?
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Most guidelines recommend surgical resection of all main duct (MD) and mixed-type (MT) intraductal papillary mucinous neoplasms (IPMNs) in suitable patients. However, there is little evidence regarding the malignancy risk of enhancing mural nodules (EMNs) that are present only in the main pancreatic duct (MPD) in patients with MD- and MT-IPMNs. Therefore, this study aimed to identify the clinical and morphological features associated with malignancy in MD- and MT-IPMNs with EMNs only in the MPD. Methods: We retrospectively enrolled 50 patients with MD- and MT-IPMNs with EMNs only in the MPD on contrast-enhanced magnetic resonance imaging. We evaluated the clinical characteristics and preoperative radiologic imaging results of MPD morphology and EMN size and analyzed the risk factors associated with malignancy. Results: Histological findings of EMNs were low-grade dysplasia (38%), malignant lesions (62%), high-grade dysplasia (34%), and invasive carcinoma (28%). On the receiver operating characteristic curve, the cutoff value of EMN size on magnetic resonance imaging for best predicting malignancy was 5 mm (sensitivity, 93.5%; specificity, 52.6%; area under the curve, 0.753). Multivariate analysis showed that only EMN >5 mm (odds ratio, 27.69; confidence interval, 2.75 to 278.73; p=0.050) was an independent risk factor for malignancy. Conclusions: EMNs of >5 mm are associated with malignancy in patients with MD- and MT-IPMNs with EMNs that are present only in the MPD, in accordance with the international consensus guidelines.
Abstract
Background/Aims: Most guidelines recommend surgical resection of all main duct (MD) and mixed-type (MT) intraductal papillary mucinous neoplasms (IPMNs) in suitable patients. However, there is little evidence regarding the malignancy risk of enhancing mural nodules (EMNs) that are present only in the main pancreatic duct (MPD) in patients with MD- and MT-IPMNs. Therefore, this study aimed to identify the clinical and morphological features associated with malignancy in MD- and MT-IPMNs with EMNs only in the MPD. Methods: We retrospectively enrolled 50 patients with MD- and MT-IPMNs with EMNs only in the MPD on contrast-enhanced magnetic resonance imaging. We evaluated the clinical characteristics and preoperative radiologic imaging results of MPD morphology and EMN size and analyzed the risk factors associated with malignancy. Results: Histological findings of EMNs were low-grade dysplasia (38%), malignant lesions (62%), high-grade dysplasia (34%), and invasive carcinoma (28%). On the receiver operating characteristic curve, the cutoff value of EMN size on magnetic resonance imaging for best predicting malignancy was 5 mm (sensitivity, 93.5%; specificity, 52.6%; area under the curve, 0.753). Multivariate analysis showed that only EMN >5 mm (odds ratio, 27.69; confidence interval, 2.75 to 278.73; p=0.050) was an independent risk factor for malignancy. Conclusions: EMNs of >5 mm are associated with malignancy in patients with MD- and MT-IPMNs with EMNs that are present only in the MPD, in accordance with the international consensus guidelines.
참고문헌 (16)
- Hyun Woo Lee, "Timing and Clinical Features of Spontaneous Decrease in Size of Small Pancreatic Cystic Lesions without High-Risk Stigmata", Gut and Liver, 14(2), pp.248~256 (2020), 거트앤리버 소화기연관학회협의회
- Tanaka M, "Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas", Pancreatology, 17, pp.738~753 (2017)
- Roch AM, "Management of mixed-type intraductal papillary mucinous neoplasm", Adv Surg, 50, pp.1~15 (2016)
- Bassi C, "Management of complications after pancreaticoduodenectomy in a high volume centre : results on 150 consecutive patients", Dig Surg, 18, pp.453~458 (2001)
- Park HM, "Perioperative transfusion in pancreatoduodenectomy: the double-edged sword of pancreatic surgeons", Medicine(Baltimore), 96, pp.e9019~ (2017)
- Winter JM, "1423 Pancreaticoduodenectomies for pancreatic cancer : a single-institution experience", J Gastrointest Surg, 10, pp.1199~1211 (2006)
- Salvia R, "Differences between main-duct and branch-duct intraductal papillary mucinous neoplasms of the pancreas", World J Gastrointest Surg, 2, pp.342~346 (2010)
- Schmidt CM, "Intraductal papillary mucinous neoplasms : predictors of malignant and invasive pathology", Ann Surg, 246, pp.644~654 (2007)
- Akita H, "Mural nodule in branch duct-type intraductal papillary mucinous neoplasms of the pancreas is a marker of malignant transformation and indication for surgery", Am J Surg, 202, pp.214~219 (2011)
- Niiya F, "Can the location of the mural nodule indicate benign or malignant in branch ducttype intraductal papillary mucinous neoplasm of the pancreas?", Pancreatology, 20, pp.1379~1385 (2020)
- Marchegiani G, "Systematic review, meta-analysis, and a high-volume center experience supporting the new role of mural nodules proposed by the updated 2017 international guidelines on IPMN of the pancreas", Surgery, 163, pp.1272~1279 (2018)
- Uehara H, "Size of mural nodule as an indicator of surgery for branch duct intraductal papillary mucinous neoplasm of the pancreas during followup", J Gastroenterol, 46, pp.657~663 (2011)
- Kawada N, "Mural nodule of 10 mm or larger as predictor of malignancy for intraductal papillary mucinous neoplasm of the pancreas : Pathological and radiological evaluations", Pancreatology, 16, pp.441~448 (2016)
- Hackert T, "Main-duct intraductal papillary mucinous neoplasm : high cancer risk in duct diameter of 5 to 9 mm", Ann Surg, 262, pp.875~881 (2015)
- Sugimoto M, "Assessment of a revised management strategy for patients with intraductal papillary mucinous neoplasms involving the main pancreatic duct", JAMA Surg, 152, pp.e163349~ (2017)
- Roch AM, "The natural history of main duct-involved, mixed-type intraductal papillary mucinous neoplasm : parameters predictive of progression", Ann Surg, 260, pp.680~690 (2014)